GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Lab] CPC cagri — Janoshik came back 98.4% against a claimed 97.5% — 54 comments in the full submission. View in context.
1.4k
c/cagrilintide·submitted 6 months ago by u/nl_verzekering

[Lab] CPC cagri — Janoshik came back 98.4% against a claimed 97.5%

Labbranch of 7 comments

Title says it — CPC cagri — Janoshik came back 98.4% against a claimed 97.5% — so here is the boring supporting detail that makes it worth anything. The relevant figures are 98.4% and 97.5%, and they come from the same log I have kept the whole time. Independent purity data on this compound is sparse compared with…

Read the full submission and all 54 comments →

This branch

7 comments, started 6 months ago
u/ledger_modMOD70 points·6 months ago

Independent result added to the log. Thank you for paying for it — there are very few on this compound.

replysharereportpermalink
[removed]52 points·6 months ago

[removed by moderator]

replysharereportpermalink
u/crosspost_bot_no29 points·6 months ago

Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.

replysharereportpermalink
u/emil_agyeman13 points·6 months ago·edited

That result is preclinical. Worth flagging, since the thread has been reading it as human data.

replysharereportpermalink
u/yannick_salinas6 points·6 months ago

That result is preclinical.

Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.

replysharereportpermalink
u/amylin_amyamylin0 points·6 months ago

Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.

Adding the standing caveat — nothing here is approved standalone and research material is not for human use.

replysharereportpermalink
u/incretin_ivypharmacology19 points·6 months ago

the co-agonism argument is about complementary mechanisms

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.